Twist Bioscience Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TWST research report →
Companywww.twistbioscience.com
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
- CEO
- Emily Marine Leproust
- IPO
- 2018
- Employees
- 923
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $3.34B
- P/E
- -40.74
- P/S
- 8.16
- P/B
- 7.28
- EV/EBITDA
- -56.93
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 52.07%
- Op Margin
- -33.90%
- Net Margin
- -19.85%
- ROE
- -17.46%
- ROIC
- -24.50%
Growth & Income
- Revenue
- $376.57M · 20.32%
- Net Income
- $-77,670,000 · 62.79%
- EPS
- $-1.30 · 63.89%
- Op Income
- $-136,259,000
- FCF YoY
- -9.34%
Performance & Tape
- 52W High
- $66.06
- 52W Low
- $23.30
- 50D MA
- $52.28
- 200D MA
- $38.63
- Beta
- 2.23
- Avg Volume
- 1.22M
Get TickerSpark's AI analysis on TWST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 26 | JOHANNESSEN JAN | other | 12,000 |
| May 12, 26 | JOHANNESSEN JAN | sell | 12,000 |
| May 12, 26 | JOHANNESSEN JAN | other | 12,000 |
| May 8, 26 | WERNER ROBERT F. | sell | 4,961 |
| May 4, 26 | Cho Dennis | sell | 1,962 |
| May 4, 26 | Leproust Emily M. | sell | 5,127 |
| May 4, 26 | Finn Patrick John | sell | 2,844 |
| May 4, 26 | Green Paula | sell | 1,116 |
| May 4, 26 | WERNER ROBERT F. | sell | 164 |
| Apr 27, 26 | Starovasnik Melissa A. | sell | 500 |
Our TWST Coverage
View all →
Twist Bioscience Corporation (TWST) drops after deep earnings miss
Twist Bioscience Corporation (TWST) drops despite revenue growth and raised guidance, as a wider-than-expected EPS loss overshadowed strong segment momentum, margin improvement, and continued sequential sales gains. This deep-dive breaks down the earnings miss, operating trends, and why investors focused on profitability over the top-line beat.
Twist Bioscience (TWST): Margin Gains, But Valuation Is Rich
Twist Bioscience is scaling revenue, expanding gross margin, and gaining traction in AI-enabled discovery, but the stock already prices in much of the progress. Our view is Hold as the company works toward profitability.
Twist Bioscience Corporation (TWST) drops on earnings misses
Twist Bioscience Corporation (TWST) drops 5.5% after reporting earnings misses, as investors react to weaker-than-expected results and reassess the stock's near-term outlook.
Want a deeper read on TWST?
Generate a full analyst-grade report — bull / bear case, price targets, valuation depth, and a complete financial breakdown.